<DOC>
	<DOCNO>NCT02382211</DOCNO>
	<brief_summary>The T-SPOT assay quantifies number peripheral blood interferon-γ produce effector T cell [ spot form cells/million peripheral blood mononuclear cell - PBMC ) ] . The T-SPOT platform technology apply diagnose monitor major disease process drive T cell response , include viral disease cytomegalovirus ( CMV ) infection ( T-SPOT.CMV assay ) allograft rejection ( T-SPOT.PRT assay ) .</brief_summary>
	<brief_title>T-SPOT.CMV T-SPOT.PRT Diagnostic Assays</brief_title>
	<detailed_description>Approximately 600 subject meet inclusion/exclusion criterion enrol prospective , non-randomized , observational study . Sample size base adequate overall number subject assess T-SPOT.PRT endpoint ( 350 ) T-SPOT.CMV endpoint ( 250 ) define population . Subjects may enrol pre-transplantation post-transplantation completion antiviral prophylaxis . Study duration : 37 month ; 25 month enroll subject 12 month ( 365 day ) patient participation . Study population : All subject enrol study men woman , age 18 year old recipient first subsequent renal transplant .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<criteria>Inclusion criterion : 1 . Active candidate recipient kidney transplant . Patients enrol posttransplant must within 6 month transplantation active CMV antiviral prophylaxis . 2 . Age ≥ 18 year . 3 . CMV serology donor recipient confirm prior enrollment . For seronegative subject ( R ) , CMV serostatus confirm within eight week prior transplant site local laboratory . 4 . Able provide TSPOT pretransplant sample maximum one month prior transplant ( interval Day 30 Day 0 ) , time enrollment occurs follow transplantation . 5 . IRB approve write Informed Consent privacy language per national regulation ( e.g. , Health Insurance Portability Accountability Act US sit ) must obtain subject legally authorize representative prior study related procedure , include screen evaluation test . Exclusion criterion : 1 . Anemia prior transplant indicate candidate blood draw . 2 . On active immunosuppression within two month prior transplant . 3 . Multiorgan transplant ( dualkidney allocation allow ) . 4 . Subject receive prior exposure CMV vaccine . 5 . Subject undergone planning undergo plasmapheresis . 6 . Subject require desensitization ABO blood type incompatibility positive T Bcell crossmatch . 7 . Subject know HIV positive . 8 . Subject know clinically significant medical psychiatric condition consider high risk participation investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CMV</keyword>
</DOC>